MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202517048785 A) filed by Ahead Therapeutics, S. L.; Fundacio Institut D'Investigacio En Ciencies De La Salut Germans Trias I Pujol; Fundacio Hospital Universitari Vall D'Hebron Institut De Recerca; and Universitat De Lleida, Barcelona, Spain, on May 20, for 'tolerogenic composition.'
Inventor(s) include Rodriguez Vidal, Silvia; Salvado Molero, Miriam; Mancera Arteu, Montserrat; Rodriguez Fernandez, Silvia; Almenara Fuentes, Lidia; Rosell Mases, Estela; Barneda Zahonero, Bruna; Dalmases Arnella, Marti; Zea Checa, Bernabe; Vives Pi, Marta; Espejo Ruiz, Carmen; Eixarch Ahufinger, Herena; and Verdaguer Autonell, Juan.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "The disclosure relates to tolerogenic liposome-based compositions and uses thereof for treating immune disorders. Said compositions comprise two populations of liposomes, wherein the first population of liposomes has a size in the range from 2 to 200 nm, the second population of liposomes has a size in the range from 500 to 2000 nm, the liposomes of the first and second populations carry one or more antigens, and the liposomal membrane of each liposome in the first and second liposome populations comprises phosphatidylserine in an amount ranging from 20 to 60% by weight with respect to the total composition of the liposome's membrane."
The patent application was internationally filed on Nov. 22, 2023, under International application No.PCT/EP2023/082656.
Disclaimer: Curated by HT Syndication.
